Merck (announced the presentation of interim data from the Phase 1b/2 KEYNOTE-365 umbrella trial investigating Keytruda, Merck's anti-PD-1 therapy, in combination with various agents for the treatment of patients with metastatic castration-resistant prostate cancer. These early findings show anti-tumor activity across three cohorts of the study, which investigated Keytruda in combination with Lynparza for Cohort A, docetaxel and prednisone for Cohort B, and enzalutamide for Cohort C - with a safety profile consistent with each therapy alone. These results are being presented at the 2019 Genitourinary Cancers Symposium in San Francisco. Based on the findings, Merck is initiating three new pivotal Phase 3 trials with Keytruda in combination with Lynparza, docetaxel and prednisone and enzalutamide. With the initiation of KEYLYNK-010, KEYNOTE-921 and KEYNOTE-641, Merck now has the only program to evaluate overall survival as a co-primary endpoint across three Phase 3 trials.